population with mild cognitive impa...

population with mild cognitive impairment taking the medication donepezil were at reduc risk of progressing to Alzheimer's disease during the first 18 month of a three-year thought when compared with their counterparts who were taking a placebo, according to a July 18 2004 recents release from the National Institutes of Health. The reduc risk of progressing from mild cognitive impairment to a diagnosis of Alzheimer's disease among participants forward donepezil no longer existed after 18 month and by means of the end of the contemplation the probability of progressing to Alzheimer's disease was the same in the couple groups.

The research compared donepezil, vitamin E, and placebo in participants with mild cognitive impairment to view whether the medications would delay or impede progression to Alzheimer's disease. During the course of the cogitation among people who did progres to Alzheimer's disease, the participants taking donepezil averaged 661 days until a diagnosis of Alzheimer's disease; a next to the first group taking vitamin E averaged 540 days from mild cognitive impairment to Alzheimer's disease; and those taking placebo averaged 484 days to Alzheimer's disease. The investigators reported a statistically significant force when donepezil was compared to placebo if it be not that said there was no apparent benefit from vitamin E

The National Institute forward Aging and the scientists conducting the research emphasized that further analyses are exigencyed to assess the practical, clinical implications of the recent data. The study is entangled and the effects appear to be time limited.

clan with mild cognitive impairment have notable memory Los and are at higher risk for developing Alzheimer's disease than those of similar age and health in the general population. Donepezil was used in the application of mind because of its current approval as a medication for treating patients already diagnosed with Alzheimer's disease. The antioxidant vitamin E has been linked in animal research to a reduction in cognitive decline and in more [i]or[/i] less population studies to reduced risk of Alzheimer's disease.

In addition to being trialed for Alzheimer's disease, study participants were assessed in specific areas of cognitive function, including orientation, Language, and attention, and in everyday function (ie, activities of daily living). These secondary analyses recommend that decline among the collection taking donepezil occurred at a slower rate in succession tests of global cognition, memory, and language than among the other participants during the first half of the contemplation but progressed at the same rate thereafter.

The Memory Impairment research was conducted nationwide at 69 sites. It involved 769 participants with mild cognitive impairment, who were followed for three years and proofed for Alzheimer's disease at six-month intervals during their 36 month in the subject of attention The average age of the participants was 73 years.

Donepezil May Have Short-Term Benefit for Mild Cognitive Impairment; More Analyses lacked to Assess Clinical Implications of fresh Data (news release, Bethesda, Md: National Institutes of Health, July 18 2004) http://www.nih.gov/news/pr/jul2004/nia-18.htm (accessed 3 Aug 2004)

COPYRIGHT 2004 Association of Operating range Nurses, Inc.

COPYRIGHT 2004 Gale Group